The global insulin delivery pens market size is predicted to increase from USD 25,578 million in 2025 and is anticipated to ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

from syringes to insulin pens, to an insulin pump, or even with an inhaler. Maintaining blood glucose levels helps reduce the risk of diabetes complications, such as blindness and the loss of limbs.

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by ...

People may choose to manage their diabetes with insulin injections ... This applies to injecting insulin with a syringe, prefilled insulin pen needle, or if you’re using an insulin pump infusion ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

Danish pharmaceutical giant Novo Nordisk has announced plans to phase out Human Mixtard, India's top-selling insulin brand.

Medtronic has submitted 510(k) applications to the U.S. Food and Drug Administration seeking clearance for an interoperable pump.

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...